Patients with osteosarcoma have a lot of medical needs that aren't being met, which is driving the market for new and effective treatments. The lack of osteosarcoma-specific medicines with few side effects gives drug companies and academics a chance to improve patient results.
Osteosarcoma study and growth change the way the market works. To make tailored and immunotherapies for osteosarcoma, drug companies, study centers, and activist groups work together.
As DNA analysis is used in osteosarcoma studies, the market is changing. Understanding genetic changes and molecular traits can lead to personalized and custom treatments for osteosarcoma. Genomic progress allows for more accurate development of therapies that are tailored to each patient.
Osteosarcoma is affected by changes in chemotherapy and tailored medicines. Osteosarcoma might be able to be cured with drugs and medicines that target certain biological pathways. These improvements make therapy more possible.
Pediatric cancer partnerships change the way the osteosarcoma market works. Collaborations speed up the search for new osteosarcoma treatments, especially for kids and teens, by sharing resources, information, and people who want to take part in clinical trials.
Patient support groups and efforts to raise understanding change the way the market works. These groups help people with osteosarcoma and their families, raise awareness, and push for money for study. Osteosarcoma becomes more well known, and people work together more in healthcare.
Osteosarcoma clinical studies that change all the time drive market growth. In clinical research, new immunotherapies and focused medicines are being tried out. The results of these tests could change how osteosarcoma is treated.
Problems with diagnosing and finding osteosarcoma change the way the market works. A late finding may make treatment less effective. Better early identification and tests help the business by making it easier to help patients and better their results.
Osteosarcoma treatments that are available and how much they cost affect how the market works. Therapy uptake is affected by how easy it is to get new medicines and how much patients and doctors are paid. These rules are very important for getting osteosarcoma drugs on the market.
Osteosarcoma Market Size was valued at USD 0.64 Billion in 2023. The Global Osteosarcoma industry is projected to grow from USD 0.69 Billion in 2024 to USD 1.21 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.39% during the forecast period (2024 - 2032).
Osteosarcoma is a common type of bone cancer that is developed in cells that are responsible for the formation of bones. In very rare conditions osteosarcoma occurs in the soft tissue outside the bones. Generally, it mostly occurs in teenagers, young adults, and older adult population.
The osteosarcoma market is primarily driven by the high incidence of osteosarcoma, rising expenditure on oncology medicine and research, and the rising demand for new treatments. However, the high cost of treatment and side-effects of chemotherapy are hampering the growth of the market.
Market Dynamics
The Osteosarcoma Market is emerging due to the high incidence of osteosarcoma. For instance, the prevalence of primary bone cancer is increasing across the world. According to the National Institutes of Health (NIH), an estimate of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. According to the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in 2018.
Moreover, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. This cumulative prevalence of osteosarcoma along with the rising geriatric population are driving the osteosarcoma market.
The Osteosarcoma Market has been segmented into type, diagnosis & treatment, end-user, and region.
On the basis of type, the Osteosarcoma Market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extraskeletal osteosarcoma. Intramedullary osteosarcoma is estimated to account for the largest market share of 80.3% during the forecast period. Intramedullary osteosarcoma is the most common type of osteosarcoma, which represents approximately 75% of all reported osteosarcoma cases recorded globally. Usually, intramedullary osteosarcoma occurs in children and adults. This type of osteosarcoma is bimodal and primarily peaks during adolescence, and the second peak occurs in adulthood. The distal femur and proximal tibia are two primary sites affected by intramedullary osteosarcoma.
On the basis of diagnosis & treatment, the osteosarcoma market has been segregated into treatment and diagnosis. The treatment segment is further segmented into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment includes limb-sparing surgery and amputation.
The diagnosis segment is further segmented into imaging, biopsies, and blood tests. The imaging segment includes computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others.
On the basis of end-user, the osteosarcoma market has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations. Its hold largest market share can be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.
The Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounted for a market share of 40.02% in 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.
Europe was the second-largest osteosarcoma market in 2018. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market.
The market in the Middle East & Africa is likely to exhibit the lowest growth due to factors such as limited access to and availability of treatment facilities. However, the high prevalence of bone cancer population would support the growth of the market in the region during the forecast period.
Prominent Players
The Prominent Players in the Market Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. The players operating in the osteosarcoma market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)